|
JP7332157B2
(ja)
|
2017-01-24 |
2023-08-23 |
ノースウェスタン ユニバーシティ |
アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体
|
|
CA3082610A1
(en)
|
2017-11-29 |
2019-06-06 |
Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
|
|
JP7340372B2
(ja)
*
|
2019-07-11 |
2023-09-07 |
浜松ホトニクス株式会社 |
光活性化アデニル酸シクラーゼ
|
|
BR112022014552A2
(pt)
*
|
2020-01-23 |
2022-10-25 |
Avirus Inc |
Polipeptídeo recombinante, composição farmacêutica, método de prevenção ou tratamento de uma infecção viral em um indivíduo que necessita do mesmo, molécula de rna, composição terapêutica, sistema de expressão, polipeptídeo recombinante para tratar infecção por sars-cov-2 e polinucleotídeo que codifica o polipeptídeo recombinante
|
|
US11518788B2
(en)
*
|
2020-07-10 |
2022-12-06 |
Avirus, Inc. |
Methods and compositions for treating and preventing viral infection
|
|
US20210236583A1
(en)
*
|
2020-02-03 |
2021-08-05 |
Yuntao Wu |
Targeting the renin-angiotensin system for treatment of environment-and pathogen-induced lung injury
|
|
TWI886211B
(zh)
*
|
2020-02-13 |
2025-06-11 |
美商西雅圖免疫公司 |
重組ace2-fc融合分子以及製造及使用彼等之方法
|
|
EP4073243A4
(en)
*
|
2020-02-13 |
2024-08-07 |
Sichuan Baili Pharmaceutical Co. Ltd. |
RECOMBINANT ECA2-FC FUSION MOLECULES, METHODS OF PREPARATION AND USE THEREOF
|
|
WO2022173424A1
(en)
*
|
2021-02-10 |
2022-08-18 |
Systimmune, Inc. |
Recombinant ace2-fc fusion molecules and methods of making and using thereof
|
|
CN115297867A
(zh)
*
|
2020-02-20 |
2022-11-04 |
理筱龙 |
人参皂甙m1作为血管收缩素调节酶的调节剂及其在治疗包括冠状病毒引起的症状的疾病或病征的用途
|
|
CN111474363A
(zh)
*
|
2020-02-22 |
2020-07-31 |
安徽华培生物科技有限公司 |
一种新型冠状病毒检测方法
|
|
WO2021174107A2
(en)
*
|
2020-02-26 |
2021-09-02 |
Northwestern University |
Soluble ace2 variants and uses therefor
|
|
JP7554837B2
(ja)
|
2020-02-27 |
2024-09-20 |
華輝安健(北京)生物科技有限公司 |
可溶性ａｃｅ２及び融合タンパク質、並びにその適用
|
|
WO2021170113A1
(zh)
*
|
2020-02-29 |
2021-09-02 |
南京金斯瑞生物科技有限公司 |
ACE-2-Fc融合蛋白治疗冠状病毒的方法
|
|
US20210284716A1
(en)
|
2020-03-11 |
2021-09-16 |
Immunitybio, Inc. |
ACE2-Fc Trap
|
|
US12285480B2
(en)
|
2020-03-11 |
2025-04-29 |
Nantcell, Inc. |
Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
|
|
US11857620B2
(en)
|
2020-03-11 |
2024-01-02 |
Immunitybio, Inc. |
Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
|
|
CN115244077B
(zh)
*
|
2020-03-11 |
2025-04-29 |
南特细胞公司 |
蛋白质治疗剂
|
|
CN116057176A
(zh)
*
|
2020-03-21 |
2023-05-02 |
赖瑞克斯生物科技公司 |
Ace2和补体途径的双特异性和三特异性功能分子及其用途
|
|
WO2021195009A1
(en)
*
|
2020-03-23 |
2021-09-30 |
Sapience Therapeutics, Inc. |
Peptide antagonists of ace2-binding proteins
|
|
CN113444710A
(zh)
*
|
2020-03-25 |
2021-09-28 |
上海英脉德医疗科技有限公司 |
ACE2-Fc融合蛋白及其用途
|
|
WO2021202456A1
(en)
*
|
2020-03-30 |
2021-10-07 |
The Wistar Institute Of Anatomy And Biology |
Synthetic soluble receptor mimics and methods of use for treatment of covid-19
|
|
WO2021197501A1
(zh)
*
|
2020-04-02 |
2021-10-07 |
创观（苏州）生物科技有限公司 |
病毒不易感动物
|
|
US20230203466A1
(en)
*
|
2020-04-03 |
2023-06-29 |
Medgenome Inc. |
Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
|
|
EP4126009A4
(en)
*
|
2020-04-03 |
2024-04-17 |
The University of North Carolina at Chapel Hill |
BINDING PROTEINS FOR USE AGAINST ACE2-TARGETED VIRUSES
|
|
WO2021216547A1
(en)
*
|
2020-04-20 |
2021-10-28 |
Sorrento Therapeutics, Inc. |
Pulmonary administration of ace2 polypeptides
|
|
WO2021237239A1
(en)
*
|
2020-05-18 |
2021-11-25 |
Northwestern University |
Active low molecular weight variant of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
|
|
US11773385B2
(en)
*
|
2020-05-19 |
2023-10-03 |
Children's Medical Center Corporation |
High-affinity human ACE2 construct for use in diagnosing and treating coronaviruses
|
|
WO2021247675A1
(en)
*
|
2020-06-02 |
2021-12-09 |
Ngm Biopharmaceuticals, Inc. |
Coronavirus-binding agents and uses thereof
|
|
DE102020207224A1
(de)
|
2020-06-09 |
2021-12-09 |
Christoph Karle |
Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon
|
|
CA3179834A1
(en)
*
|
2020-06-25 |
2021-12-30 |
David S. Block |
Ace2-fc fusion proteins and methods of use
|
|
WO2022008642A1
(en)
|
2020-07-08 |
2022-01-13 |
Apeiron Biologics Ag |
Treatment of sars-cov-2 infection with a combination of targets
|
|
WO2022012688A1
(en)
*
|
2020-07-17 |
2022-01-20 |
Shenzhen Bay Laboratory |
Ace2-ig fusion variants
|
|
KR102492081B1
(ko)
|
2020-07-28 |
2023-01-26 |
재단법인대구경북과학기술원 |
코로나바이러스 감염증 covid-19 치료용 펩타이드 및 이의 용도
|
|
US20220041660A1
(en)
*
|
2020-08-06 |
2022-02-10 |
University Of Delaware |
Compositions and methods for sequestering viral particles in respiratory tract
|
|
WO2022029011A1
(en)
*
|
2020-08-06 |
2022-02-10 |
BioNTech SE |
Binding agents for coronavirus s protein
|
|
WO2022035998A1
(en)
*
|
2020-08-11 |
2022-02-17 |
City Of Hope |
Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
|
|
JP7635370B2
(ja)
*
|
2020-10-01 |
2025-02-25 |
システィミューン， インク． |
組換えａｃｅ２－ｆｃ融合分子、その製造方法及びその使用
|
|
WO2022075667A1
(ko)
*
|
2020-10-05 |
2022-04-14 |
한양대학교 산학협력단 |
안정화된 ace2 변이체, 이를 이용한 ace2-fc 융합단백질 및 covid-19 예방 또는 치료용 약학 조성물
|
|
WO2022082217A1
(en)
*
|
2020-10-16 |
2022-04-21 |
Eureka Therapeutics, Inc. |
Compositions for preventing or treating viral and other microbial infections
|
|
WO2022108013A1
(ko)
*
|
2020-11-20 |
2022-05-27 |
재단법인대구경북과학기술원 |
코로나바이러스 감염증 covid-19 치료제 단백질 ctp 알파, ctp 베타, ctp 감마, ctp 델타 및 이의 용도
|
|
CA3200885A1
(en)
|
2020-11-23 |
2022-05-27 |
Genentech, Inc. |
Methods for modulating host cell surface interactions with sars-cov-2
|
|
WO2022119380A1
(ko)
*
|
2020-12-03 |
2022-06-09 |
주식회사 유틸렉스 |
신규한 ace2 변이체 및 그의 이용
|
|
EP4011387A1
(en)
*
|
2020-12-11 |
2022-06-15 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2
|
|
WO2022159433A1
(en)
|
2021-01-20 |
2022-07-28 |
Singh Biotechnology, Llc |
Therapeutics directed against coronavirus
|
|
CA3206022A1
(en)
*
|
2021-01-26 |
2022-08-04 |
Traian Sulea |
Ace2-receptor ectodomain fusion molecules and uses thereof
|
|
WO2022165246A1
(en)
*
|
2021-01-29 |
2022-08-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and method of use of mutant ace2 decoy variants
|
|
WO2022207918A1
(en)
|
2021-04-02 |
2022-10-06 |
Apeiron Biologics Ag |
COVID-19 Therapy
|
|
WO2022246041A2
(en)
*
|
2021-05-20 |
2022-11-24 |
Achelois Biopharma, Inc. |
Compositions and methods for multivalent surface display on enveloped particles
|
|
CN113324933B
(zh)
*
|
2021-06-01 |
2022-07-26 |
浙江大学 |
一种检测血管紧张素转换酶的方法及其应用
|
|
WO2022271863A1
(en)
*
|
2021-06-23 |
2022-12-29 |
Chan Zuckerberg Biohub, Inc. |
Coronavirus neutralizing compositions and associated methods
|
|
WO2023108040A2
(en)
*
|
2021-12-09 |
2023-06-15 |
Gliknik Inc. |
Ace2-fc fusion proteins and methods of use
|
|
EP4508077A4
(en)
|
2022-04-14 |
2026-03-25 |
Invisishield Tech Ltd |
COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS
|
|
CA3256035A1
(en)
|
2022-04-14 |
2023-10-19 |
Invisishield Technologies Ltd. |
COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS
|
|
EP4335870A1
(en)
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptide therapeutics against sars-cov-2 spike protein
|
|
CN116023509A
(zh)
*
|
2022-11-18 |
2023-04-28 |
中国药科大学 |
一种融合蛋白及其应用
|
|
DE202023100085U1
(de)
|
2023-01-09 |
2023-02-03 |
Sundararajan Gothandam |
Eine doppelte Blockade des Renin-Angiotensin-Systems zur Verringerung der frühen Veränderungen der diabetischen Retinopathie und Nephropathie
|
|
CN118085110A
(zh)
*
|
2024-04-02 |
2024-05-28 |
中国药科大学 |
一种靶向肿瘤的融合蛋白及其应用
|